# Post-Authorization Observational Study to Evaluate Cognition and Fatigue in Relapsing-remitting Multiple Sclerosis (RRMS) Patients Treated With Rebif®

> **NCT01075880** · — · COMPLETED · sponsor: **Merck KGaA, Darmstadt, Germany** · enrollment: 300 (actual)

## Conditions studied

- Multiple Sclerosis, Relapsing-Remitting

## Interventions

- **DRUG:** Rebif (Interferon beta-1a)

## Key facts

- **NCT ID:** NCT01075880
- **Lead sponsor:** Merck KGaA, Darmstadt, Germany
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2009-05
- **Primary completion:** 2013-06
- **Final completion:** 2013-06
- **Target enrollment:** 300 (ACTUAL)
- **Last updated:** 2013-09-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01075880

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01075880, "Post-Authorization Observational Study to Evaluate Cognition and Fatigue in Relapsing-remitting Multiple Sclerosis (RRMS) Patients Treated With Rebif®". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01075880. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*